Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis - Drugs.com MedNews
Links shared publicly online about this topic.
- 485total visits
Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis - Drugs.com MedNews
- Relative mean improvement in lung function of approximately 17 from baseline compared to placebo achieved by people treated with VX-770 mean absolute improvem
View full resource at drugs.com
Tags: Lung, Cystic Fibrosis, Disease and Condition, Drug, Phase 3 Clinical Trial, disease
Most Recently Shared on February 23, 2011 at 1:14 pm By:
Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Function (FEV1) and Other Measu... http://bit.ly/dQh7pL #drug
Advertisement
